Medtronic plc.

Medtronic develops and sells medical devices across three main areas: cardiovascular products (pacemakers, heart valves, stent grafts), neuroscience products (spinal implants, brain stimulation devices, pain management systems), and medical-surgical products (surgical staplers, robotic surgery platforms, insulin pumps). The company operates globally, selling to hospitals, physicians, and patients through a network spanning the United States, Ireland, and international markets. With 95,000 employees, Medtronic serves specialists ranging from cardiologists and neurosurgeons to diabetes care providers.

Medtronic is a $116 billion Irish-headquartered medical device giant that makes implantable heart devices, surgical tools, spinal products, and diabetes management systems [Yahoo Finance]. The company just beat earnings expectations and raised its full-year outlook while committing over $700 million to expand its cardiac technology and robotic surgery platforms [Wall Street Journal]. Twenty-five analysts covering the company average a 'buy' rating, with a mean price target of $98.84 [Analyst consensus].

Medtronic is financially healthy with strong cash generation, moderate debt levels, and improving profitability.